Investing.com -- J.P. Morgan has reinstated coverage on 14 large-cap biotechnology companies, arguing the sector is entering a major inflection point as pipeline successes increasingly translate into profitable and diversified commercial businesses.

The bank said several biotech firms are now achieving or nearing sustained profitability, supported by expanding product portfolios, strong clinical pipelines, and potential business development activity.

The firm assigned Overweight ratings to companies including Vertex Pharmaceuticals Inc (NASDAQ: VRTX), Alnylam Pharmaceuticals Inc (NASDAQ: ALNY), BeOne Medicines AG DRC (NASDAQ: ONC), United Therapeutics Corporation (NASDAQ: UTHR), Insmed Inc (NASDAQ: INSM), Ascendis Pharma AS (NASDAQ: ASND), Jazz Pharmaceuticals PLC (NASDAQ: JAZZ), Ionis Pharmaceuticals Inc (NASDAQ: IONS), Biomarin Pharmaceutical Inc (NASDAQ: BMRN) and Mirum Pharmaceuticals Inc (NASDAQ: MIRM), while maintaining Neutral ratings on BioNTech SE (NASDAQ: BNTX), Incyte Corporation (NASDAQ: INCY) and Halozyme Therapeutics. The bank initiated an Underweight rating on Moderna.

J.P. Morgan highlighted Vertex as a “clear pivot” story, citing its expansion beyond cystic fibrosis into kidney disease and pain management, with a $515 price target. Alnylam received a $420 target as analysts pointed to the rapid growth of its Amvuttra franchise and improving profitability.

BeOne Medicines was praised for continued Brukinsa momentum and strong operating leverage, while United Therapeutics was backed by confidence in Tyvaso uptake in idiopathic pulmonary fibrosis and ralinepag’s opportunity in pulmonary arterial hypertension.

The bank also identified Insmed as a compelling opportunity following a sharp share pullback, forecasting strong growth from Brinsupri and its TPIP pipeline. Meanwhile, Ascendis Pharma was seen benefiting from the strong launch of Yorvipath, which analysts expect will rapidly accelerate profitability.

On the cautious side, J.P. Morgan warned that Moderna’s recent rally already prices in optimism around its cancer vaccine program, while ongoing cash burn remains a concern. BioNTech was viewed as lacking a near-term catalyst despite its large cash position and expanding oncology pipeline.

The note also emphasized that many of these biotech companies are entering a new phase marked by improving margins, expanding therapeutic footprints, and a steady stream of upcoming clinical catalysts, including high-profile cardiovascular outcomes trials and oncology readouts expected later this year.